WashU Medicine Mar 6 2026 The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulations of a harmful protein, amyloid, in the brain and require high-dose, once- or twice-monthly infusions of the medication. Now, to reduce the frequency of treatment and potentially improve the efficacy of an anti-amyloid therapy, researchers at